Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Elgebaly, Ahmed; Radwan, Ibrahim; AboElnas, Mohamed M; Ibrahim, Hamza H; Eltoomy, Moutaz; Atta, Ahmed A; Mesalam, Hend A; Sayed, Alaa A; Othman, Ayman M.

doi:10.15403/jgld.2014.1121.261.ely

Cited by 73 publications

(61 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Resveratrol (3,5,4′-trihydroxy-trans-stilbene, C14H12O3, molar mass: 228.25 g/mol) is a non-flavonoid phenol ( Figure 9 ) particularly concentrated in the grape skin peel, but also in the extracts of Polygonum cuspidatum , poorly orally bioavailable (if not chemically modified), characterized by an important antioxidant, vasoprotective (both cerebral and peripheral) and insulin-sensitizing activity [ 73 , 74 ]. Preliminary clinical data appear to contradict preclinical literature, suggesting a potential efficacy of resveratrol in improving NAFLD-related parameters [ 75 ]. However, these studies are usually short (too short to have an impact on the liver structure) and are conducted with resveratrol doses incompatible with the insulin-sensitizing action that could improve NAFLD.…”

Section: Resultsmentioning

confidence: 99%

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

2018

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients. Almost 1/3 of NAFLD evolves in Non-Alcoholic SteatoHepatitis (NASH), and this can lead to fibrosis and cirrhosis of the liver. However, the main causes of mortality of patients with NAFLD are cardiovascular diseases. At present, there are no specific drugs approved on the market for the treatment of NAFLD, and the treatment is essentially based on optimization of lifestyle. However, some nutraceuticals could contribute to the improvement of lipid infiltration of the liver and of the related anthropometric, haemodynamic, and/or biochemical parameters. The aim of this paper is to review the available clinical data on the effect of nutraceuticals on NAFLD and NAFLD-related parameters. Relatively few nutraceutical molecules have been adequately studied for their effects on NAFLD. Among these, we have analysed in detail the effects of silymarin, vitamin E, vitamin D, polyunsaturated fatty acids of the omega-3 series, astaxanthin, coenzyme Q10, berberine, curcumin, resveratrol, extracts of Salvia milthiorriza, and probiotics. In conclusion, Silymarin, vitamin E and vitamin D, polyunsaturated fatty acids of the omega-3 series, coenzyme Q10, berberine and curcumin, if well dosed and administered for medium–long periods, and associated to lifestyle changes, could exert positive effects on NAFLD and NAFLD-related parameters.

show abstract

Section: Resultsmentioning

confidence: 99%

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

2018

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of 283 subjects with type 2 diabetes reported that high-dose resveratrol (≥100 mg/day) supplementation improved the fasting plasma glucose level [ 38 ]. Nevertheless, other reports of meta-analysis fail to show the beneficial effects of resveratrol on lipid profile ( n = 763 subjects) [ 39 ] and NAFLD ( n = 158 subjects) [ 40 ].…”

Section: Health Benefits Of Resveratrol Against Metabolic Syndromementioning

confidence: 99%

Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?

Tain

Hsu

2018

IJMS

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a mounting epidemic worldwide. MetS can start in early life, in a microenvironment that is now known as the developmental origins of health and disease (DOHaD). The concept of DOHaD also offers opportunities for reprogramming strategies that aim to reverse programming processes in early life. Resveratrol, a polyphenolic compound has a wide spectrum of beneficial effects on human health. In this review, we first summarize the epidemiological and experimental evidence supporting the developmental programming of MetS. This review also presents an overview of the evidence linking different molecular targets of resveratrol to developmental programming of MetS-related disorders. This will be followed by studies documenting resveratrol as a reprogramming agent to protect against MetS-related disorders. Further clinical studies are required in order to bridge the gap between animal models and clinical trials in order to establish the effective dose and therapeutic duration for resveratrol as a reprogramming therapy on MetS disorders from developmental origins.

show abstract

“…In contrast to these encouraging studies, another very recent, randomized, clinical trial from Denmark including 28 patients with overweight found no indication that RES treatment (1.5 g RES/day for 6 months) had any consistent therapeutic effects (63). In line, a recent systematic review and meta-analysis study published during the revision of the current review concluded that the current evidence was insufficient to support the efficacy of resveratrol in the management of NAFLD (64). A detailed search in the Clinicaltrials.gov registry for clinical RES trials led to the identification of 13 clinical trials when using the search terms "resveratrol" and "liver".…”

Section: Res As a Therapeutically Effective Drug In Human Liver Diseasementioning

confidence: 56%

Resveratrol: Is It Really Good for Liver Health?

Weiskirchen¹,

Weiskirchen²

2017

Hepat Mon

View full text Add to dashboard Cite

Context: Resveratrol is a natural occurring stilbene present in a limited number of dietary food products and beverages. It is assumed that resveratrol has health-promoting effects by lowering low-density lipoprotein (LDL) cholesterol, improving microcirculation, and inhibiting platelet aggregation. Altogether, these beneficial effects lower the risk of cardiovascular disease. The "French paradox" assumes that a diet with moderate consumption of red wine lowers the risk of cancer and cardiovascular disease. Based on its healthful activities, a large number of studies were performed during the last decades investigating potential biological effects of resveratrol on liver homeostasis and its potential application as a hepatoprotective drug. Objectives: The current study aimed at discussing the proposed therapeutic attributes of resveratrol on liver health and its postulated mode of activity. Evidence Acquisition: To conduct the current study, the PubMed full-text archive depository for articles presenting data on resveratrol in liver health and disease was searched. Results: Out of the 9268 published articles on resveratrol, a total of 742 articles focused on liver. Among them, 352 articles investigated potential therapeutic activities. Although some of the reported in vitro and in vivo benefits of resveratrol were highly encouraging, well-designed clinical studies were missing. Conclusions: Presently, it is still premature to advise nutritional supplementation of resveratrol to cure hepatic diseases. Moreover, uncritical recommendation to drink wine as a liver health-promoting beverage should be avoided.

show abstract

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

Cited by 73 publications

References 18 publications

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?

Resveratrol: Is It Really Good for Liver Health?

Contact Info

Product

Resources

About